Skip to main content

WELLlife™ COVID-19 / Influenza A&B Test

WELLlife™ COVID-19 / Influenza A&B Test

A reliable and cost-effective solution, the COVID-19 / Influenza A&B Test is an essential tool for timely management of viral infections.

  • FDA EUA240004
  • For Emergency Use Authorization (EUA) Only
  • For In Vitro Diagnostic Use
  • For Use with Anterior Nasal Swab Specimens
Contact Sales
WELLlife™ COVID-19 / Influenza A&B Test
Connect With Us

About

 

The ability to quickly and accurately differentiate between COVID-19 and flu symptoms is more crucial than ever. This innovative Combo COVID-19 and Flu POC Test empowers providers with a convenient and reliable solution for in-clinic testing.

 

 

Features

  • Rapid Results, Batch Testing: Quick and easy workflow with results in just 10 minutes.
  • Extended Detection Window: Offers a broader detection window for differentiation of SARS-COV-2, influenza A, and influenza B antigens within five days of symptom onset.
  • Quality Assurance: The outstanding clinical performance, including built-in kit controls for external quality testing, enables physicians to make quicker and more confident decisions.
  • Reliable: With a COVID-19 clinical sensitivity of 87.5%, Flu A clinical sensitivity of 85.9% and Flu B clinical sensitivity of 86.8%,  this combo test allows users to accurately differentiate between COVID-19, Flu A, and Flu B.
 
 

 

Product Image

 

Specifications

 

Product CodeEUA240004
Items Per Box25
Specimen TypeNasal Swab
Result Time10 Minutes
Clinical SensitivityCOVID - 87.5%, FLU A - 85.9%, FLU B - 86.8%
Test ComponentsIndividually packaged test cassettes, Test casettes, Prefilled extraction buffer, Sterile swabs, Positive control swab, Negative control swab, Tube holder, Package insert, Quick Reference Instruction

Intended Use

 

The WELLlife™ COVID-19 / Influenza A&B Test is a lateral flow immunochromatographic

assay intended for in vitro rapid, simultaneous qualitative detection and differentiation of

influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen

directly from anterior nasal swab specimens of individuals with signs and symptoms of

respiratory infection consistent with COVID-19 within the first five (5) days of symptom onset

when tested at least twice over three days with at least 48 hours between tests. Clinical

signs and symptoms of respiratory viral infection due to SARS-CoV-2 and influenza can be

similar. Testing is limited to laboratories certified under the Clinical Laboratory Improvement

Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform

moderate, high or waived complexity tests.

Contact Sales & Customer Service

 

 

 

Call Sales 

Customer Service

Support Contact Form

 

+1 (657) 296-6106
Weekdays 9 AM - 8 PM EST • Weekends 9 AM - 3 PM EST)